Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients

Annals of Hepatology

Volumn 12, Issue 5, 2013, Pages 766-773

  Gaba, Ron C ^a   Kallwitz, Eric R ^b   Parvinian, Ahmad ^a   Bui, James T ^a   Von Roenn, Natasha M ^b   Berkes, Jamie L ^b   Cotler, Scott J ^b  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Liver; Outcome; Transplantation

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CREATININE; SORAFENIB; YTTRIUM 90;

ADULT; AGE; ALCOHOL CONSUMPTION; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BODY MASS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; CREATININE BLOOD LEVEL; EARLY DIAGNOSIS; ESOPHAGUS VARICES BLEEDING; ETHNICITY; FEMALE; FOLLOW UP; GENDER; HEALTH CARE ACCESS; HEALTH IMPACT ASSESSMENT; HEALTH INSURANCE; HEPATIC ENCEPHALOPATHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TUMOR GROWTH; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERDISCIPLINARY COMMUNICATION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE TEAM; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84885761601     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31318-3     Document Type: Article

References (18)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
2. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
4. Raoul JL. Natural history of hepatocellular carcinoma and current treatment options. Semin Nucl Med 2008; 38: S13-s18.
5. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
6. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
8. Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant 2012; 26: E359-E364.
9. Dhanasekaran R, Khanna V, Kooby DA, Spivey JR, Parekh S, Knechtle SJ, Carew JD, et al. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 1197-204; quiz 204.
10. Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, Sanyal AJ, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008; 121: 119-26.
11. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52: 132-41.
12. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
13. Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 2008; 247: 666-73.
14. Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, Corvera CU. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 2008; 10: 405-11.
15. Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, Ramirez AJ. Multidisciplinary team working in cancer: what is the evidence? BMJ 2010; 340: c951.
16. Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr 2010; 2010: 72-80.
17. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2012; 6: 173-85.
18. 2010 Annual Report of the U. S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville MD, 2011.